Cadrenal Therapeutics to attend BIO International Convention 2026 partnering event

Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics, Inc.

CVKD

0.00
  • Cadrenal will attend the BIO International Convention 2026 Partnering Event in San Diego on June 22-25, 2026.
  • Management plans partnering meetings to discuss development and commercialization options for CAD-1005, a Phase 3-ready 12-LOX inhibitor for HIT.
  • Talks will also cover tecarfarin, a late-stage oral anticoagulant with FDA Orphan Drug and Fast Track designations in ESRD-AFib, LVAD patients.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cadrenal Therapeutics Inc. published the original content used to generate this news brief on June 03, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.